ABSTRACT BACKGROUND Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic
. However, most subjects included in these genetic analyses were initially free of cardiovascular disease, few were treated with a statin, and none had recent ACS.
Although the efficacy of intensive statin therapy after ACS has been firmly established in both shortterm and long-term studies (1, 3) , residual risk remains high despite such treatment (2, 16) . Statins reduce triglyceride-rich lipoproteins along with LDL-C; however, it remains uncertain whether triglycerides predict residual risk after ACS in patients under effective statin treatment, and thus whether triglyceride-rich lipoproteins should be a target for additional therapy. In JELIS (Japan EPA Lipid Intervention Study), eicosapentaenoic acid plus low-dose statin resulted in an approximately 5% reduction in triglycerides and a 19% reduction in coronary events, compared with low-dose statin alone (17) . Benefit was demonstrated in a subgroup of patients with established coronary disease, but patients with ACS were not studied. In the current study, we examined relationships between fasting triglycerides and cardiovascular risk after ACS in 2 large trials of patients treated with statins.
METHODS
The design and principal results of the dal-OUTCOMES (A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome) and MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trials have been described previously (1, 2, 18, 19) . The institutional review boards at each participating site approved the studies, and all subjects gave informed consent.
In brief, dal-OUTCOMES was a randomized, Table 1 . In dal-OUTCOMES, there were larger proportions of male and hypertensive patients and fewer current smokers than in MIRACL. Coronary revascularization for the index ACS event was performed before random assignment in more than 90% of patients in dal-OUTCOMES but was an exclusion criterion in MIRACL. The use of platelet P2Y 12 antagonists, b-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was more frequent in dal-OUTCOMES than in MIRACL.
RESULTS

Baseline characteristics of the patients are shown in
Prior to random assignment, 97% of patients in dal-OUTCOMES were treated with a statin, compared with none in MIRACL. Table 2 shows lipid levels at random assignment and on assigned treatment in the 2 trials. In dal-OUTCOMES, the median triglyceride concentration at random assignment was 115 mg/dl. On treatment with dalcetrapib or placebo, triglyceride levels changed minimally from baseline and remained similar in both groups (median 111 and 116 mg/dl, respectively). To convert values for triglycerides to mmol/l, multiply by 0.0113. To convert values for cholesterol to mmol/l, multiply by 0.0259. *Measured 1 month after random assignment in dal-OUTCOMES and 6 weeks after random assignment in MIRACL. †p < 0.001 vs. level at random assignment. 
MIRACL ¼ Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering; other abbreviations as in Figure 1 . 
